{"pmid":32162702,"title":"2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis.","text":["2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis.","BACKGROUND: To study the clinical data, discharge rate, and fatality rate of COVID-19 patients for clinical help. METHODS: The clinical data of COVID-19 patients from December 2019 to February 2020 were retrieved from four databases. We statistically analyzed the clinical symptoms and laboratory results of COVID-19 patients and explained the discharge rate, fatality rate with a single-arm meta-analysis. RESULTS: The available data of 1994 patients in 10 literatures were included in our study. The main clinical symptoms of COVID-19 patients were fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), expectoration (28.2%), dyspnea (21.9%). Minor symptoms include headache or dizziness: (12.1%) diarrhea (4.8%), nausea, and vomiting (3.9%). The results of laboratory results showed that the lymphocytopenia (64.5%), increase of CRP (44.3%), increase of LDH (28.3%), and leukocytopenia (29.4%) were more common. CONCLUSIONS: The results of single-arm meta-analysis showed that: the male took a larger percentage in the gender distribution of COVID-19 patients 60%[95%CI (0.54,0.65)], the discharge rate of COVID-19 patients was 42%[95%CI (0.29,0.55)], and the fatality rate was 7%[95%CI (0.04,0.10)]. This article is protected by copyright. All rights reserved.","J Med Virol","Li, Long-Quan","Huang, Tian","Wang, Yong-Qing","Wang, Zheng-Ping","Liang, Yuan","Huang, Tao-Bi","Zhang, Hui-Yun","Sun, Wei-Ming","Wang, Yu-Ping","32162702"],"abstract":["BACKGROUND: To study the clinical data, discharge rate, and fatality rate of COVID-19 patients for clinical help. METHODS: The clinical data of COVID-19 patients from December 2019 to February 2020 were retrieved from four databases. We statistically analyzed the clinical symptoms and laboratory results of COVID-19 patients and explained the discharge rate, fatality rate with a single-arm meta-analysis. RESULTS: The available data of 1994 patients in 10 literatures were included in our study. The main clinical symptoms of COVID-19 patients were fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), expectoration (28.2%), dyspnea (21.9%). Minor symptoms include headache or dizziness: (12.1%) diarrhea (4.8%), nausea, and vomiting (3.9%). The results of laboratory results showed that the lymphocytopenia (64.5%), increase of CRP (44.3%), increase of LDH (28.3%), and leukocytopenia (29.4%) were more common. CONCLUSIONS: The results of single-arm meta-analysis showed that: the male took a larger percentage in the gender distribution of COVID-19 patients 60%[95%CI (0.54,0.65)], the discharge rate of COVID-19 patients was 42%[95%CI (0.29,0.55)], and the fatality rate was 7%[95%CI (0.04,0.10)]. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Li, Long-Quan","Huang, Tian","Wang, Yong-Qing","Wang, Zheng-Ping","Liang, Yuan","Huang, Tao-Bi","Zhang, Hui-Yun","Sun, Wei-Ming","Wang, Yu-Ping"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32162702","week":"202011|Mar 09 - Mar 15","doi":"10.1002/jmv.25757","keywords":["2019-nCoV","COVID-19","clinical characteristics","discharge rate","fatality rate","meta-analysis"],"source":"PubMed","locations":["fatigue","myalgia"],"weight":0,"_version_":1661359647903186944,"score":6.7365713,"similar":[{"pmid":32108351,"title":"Clinical characteristics of 50 466 hospitalized patients with 2019-nCoV infection.","text":["Clinical characteristics of 50 466 hospitalized patients with 2019-nCoV infection.","We aim to summarize reliable evidence of evidence-based medicine for the treatment and prevention of the 2019 novel coronavirus (2019-nCoV) by analyzing all the published studies on the clinical characteristics of patients with 2019-nCoV. PubMed, Cochrane Library, Embase, and other databases were searched. Several studies on the clinical characteristics of 2019-nCoV infection were collected for meta-analysis. Ten studies were included in the meta-analysis, including a total number of 50 466 patients with 2019-nCoV infection. Meta-analysis shows that among these patients, the incidence of fever was 89.1%, the incidence of cough was 72.2%, and the incidence of muscle soreness or fatigue was 42.5%. The incidence of acute respiratory distress syndrome (ARDS) was 14.8%, the incidence of abnormal chest computer tomography (CT) was 96.6%, the percentage of severe cases in all infected cases was 18.1%, and the case fatality rate of patients with 2019-nCoV infection was 4.3%. Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination. Several people have muscle soreness or fatigue as well as ARDS. Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients. The case fatality rate of patients with 2019-nCoV infection is lower than that of the severe acute respiratory syndrome and Middle East respiratory syndrome.","J Med Virol","Sun, Pengfei","Qie, Shuyan","Liu, Zongjian","Ren, Jizhen","Li, Kun","Xi, Jianing","32108351"],"abstract":["We aim to summarize reliable evidence of evidence-based medicine for the treatment and prevention of the 2019 novel coronavirus (2019-nCoV) by analyzing all the published studies on the clinical characteristics of patients with 2019-nCoV. PubMed, Cochrane Library, Embase, and other databases were searched. Several studies on the clinical characteristics of 2019-nCoV infection were collected for meta-analysis. Ten studies were included in the meta-analysis, including a total number of 50 466 patients with 2019-nCoV infection. Meta-analysis shows that among these patients, the incidence of fever was 89.1%, the incidence of cough was 72.2%, and the incidence of muscle soreness or fatigue was 42.5%. The incidence of acute respiratory distress syndrome (ARDS) was 14.8%, the incidence of abnormal chest computer tomography (CT) was 96.6%, the percentage of severe cases in all infected cases was 18.1%, and the case fatality rate of patients with 2019-nCoV infection was 4.3%. Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination. Several people have muscle soreness or fatigue as well as ARDS. Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients. The case fatality rate of patients with 2019-nCoV infection is lower than that of the severe acute respiratory syndrome and Middle East respiratory syndrome."],"journal":"J Med Virol","authors":["Sun, Pengfei","Qie, Shuyan","Liu, Zongjian","Ren, Jizhen","Li, Kun","Xi, Jianing"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32108351","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25735","keywords":["2019-nCoV","clinical symptoms","coronavirus","meta-analysis"],"source":"PubMed","locations":["Diarrhea"],"topics":["Mechanism","Case Report"],"weight":1,"_version_":1661359647496339456,"score":287.58618},{"pmid":32087623,"title":"[Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with 2019 novel coronavirus pneumonia].","text":["[Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with 2019 novel coronavirus pneumonia].","Objective: To raise awareness about 2019 novel coronavirus pneumonia (NCP) and reduce missed diagnosis rate and misdiagnosis rate by comparing the clinical characteristics between RNA positive and negative patients clinically diagnosed with NCP. Methods: From January 2020 to February 2020, 54 patients who were newly diagnosed with NCP in Wuhan Fourth Hospital were included in this study. RT-PCR method was used to measure the level of 2019-nCov RNA in pharyngeal swab samples of these patients. The patients were divided into RNA positive and negative group, and the differences of clinical, laboratory, and radiological characteristics were compared. Results: There were 31 RNA of 2019-nCov positive cases, and 23 negative cases. Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs.52.17%) , cough (80.64% vs.95.65%) , fatigue (61.30% vs.56.52%) , chest distress (77.42% vs.73.91%) . Some other symptoms were headache, myalgia, dyspnea, diarrhea, nausea and vomiting. The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement. There was no statistically significant difference in other clinical characteristics except for dyspnea between two groups. Conclusions: RNA positive and negative NCP patients shared similar clinical symptoms, while RNA positive NCP patients tended to have dyspnea. Therefore, we should improve the understanding of NCP to prevent missed diagnosis and misdiagnosis; In addition, more rapid and accurate NCP diagnostic approaches should be further developed.","Zhonghua Jie He He Hu Xi Za Zhi","Li, Y Y","Wang, W N","Lei, Y","Zhang, B","Yang, J","Hu, J W","Ren, Y L","Lu, Q F","32087623"],"abstract":["Objective: To raise awareness about 2019 novel coronavirus pneumonia (NCP) and reduce missed diagnosis rate and misdiagnosis rate by comparing the clinical characteristics between RNA positive and negative patients clinically diagnosed with NCP. Methods: From January 2020 to February 2020, 54 patients who were newly diagnosed with NCP in Wuhan Fourth Hospital were included in this study. RT-PCR method was used to measure the level of 2019-nCov RNA in pharyngeal swab samples of these patients. The patients were divided into RNA positive and negative group, and the differences of clinical, laboratory, and radiological characteristics were compared. Results: There were 31 RNA of 2019-nCov positive cases, and 23 negative cases. Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs.52.17%) , cough (80.64% vs.95.65%) , fatigue (61.30% vs.56.52%) , chest distress (77.42% vs.73.91%) . Some other symptoms were headache, myalgia, dyspnea, diarrhea, nausea and vomiting. The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement. There was no statistically significant difference in other clinical characteristics except for dyspnea between two groups. Conclusions: RNA positive and negative NCP patients shared similar clinical symptoms, while RNA positive NCP patients tended to have dyspnea. Therefore, we should improve the understanding of NCP to prevent missed diagnosis and misdiagnosis; In addition, more rapid and accurate NCP diagnostic approaches should be further developed."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Li, Y Y","Wang, W N","Lei, Y","Zhang, B","Yang, J","Hu, J W","Ren, Y L","Lu, Q F"],"date":"2020-02-24T11:00:00Z","year":2020,"_id":"32087623","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112147-20200214-00095","keywords":["2019 novel coronavirus","clinical characteristics","novel coronavirus pneumonia"],"source":"PubMed","locations":["dyspnea","diarrhea","myalgia"],"topics":["Mechanism"],"weight":1,"_version_":1661359647411404801,"score":273.42657},{"pmid":32179124,"title":"Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.","text":["Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.","INTRODUCTION: An epidemic of Coronavirus Disease 2019 (COVID-19) began in December 2019 in China leading to a Public Health Emergency of International Concern (PHEIC). Clinical, laboratory, and imaging features have been partially characterized in some observational studies. No systematic reviews on COVID-19 have been published to date. METHODS: We performed a systematic literature review with meta-analysis, using three databases to assess clinical, laboratory, imaging features, and outcomes of COVID-19 confirmed cases. Observational studies and also case reports, were included, and analyzed separately. We performed a random-effects model meta-analysis to calculate the pooled prevalence and 95% confidence interval (95%CI). RESULTS: 660 articles were retrieved for the time frame (1/1/2020-2/23/2020). After screening, 27 articles were selected for full-text assessment, 19 being finally included for qualitative and quantitative analyses. Additionally, 39 case report articles were included and analyzed separately. For 656 patients, fever (88.7%, 95%CI 84.5-92.9%), cough (57.6%, 40.8-74.4%) and dyspnea (45.6%, 10.9-80.4%) were the most prevalent manifestations. Among the patients, 20.3% (95%CI 10.0-30.6%) required intensive care unit (ICU), 32.8% presented with acute respiratory distress syndrome (ARDS) (95%CI 13.7-51.8), 6.2% (95%CI 3.1-9.3) with shock. Some 13.9% (95%CI 6.2-21.5%) of hospitalized patients had fatal outcomes (case fatality rate, CFR). CONCLUSION: COVID-19 brings a huge burden to healthcare facilities, especially in patients with comorbidities. ICU was required for approximately 20% of polymorbid, COVID-19 infected patients and hospitalization was associated with a CFR of over 13%. As this virus spreads globally, countries need to urgently prepare human resources, infrastructure and facilities to treat severe COVID-19.","Travel Med Infect Dis","Rodriguez-Morales, Alfonso J","Cardona-Ospina, Jaime A","Gutierrez-Ocampo, Estefania","Villamizar-Pena, Rhuvi","Holguin-Rivera, Yeimer","Escalera-Antezana, Juan Pablo","Alvarado-Arnez, Lucia Elena","Bonilla-Aldana, D Katterine","Franco-Paredes, Carlos","Henao-Martinez, Andres F","Paniz-Mondolfi, Alberto","Lagos-Grisales, Guillermo J","Ramirez-Vallejo, Eduardo","Suarez, Jose A","Zambrano, Lysien I","Villamil-Gomez, Wilmer E","Balbin-Ramon, Graciela J","Rabaan, Ali A","Harapan, Harapan","Dhama, Kuldeep","Nishiura, Hiroshi","Kataoka, Hiromitsu","Ahmad, Tauseef","Sah, Ranjit","32179124"],"abstract":["INTRODUCTION: An epidemic of Coronavirus Disease 2019 (COVID-19) began in December 2019 in China leading to a Public Health Emergency of International Concern (PHEIC). Clinical, laboratory, and imaging features have been partially characterized in some observational studies. No systematic reviews on COVID-19 have been published to date. METHODS: We performed a systematic literature review with meta-analysis, using three databases to assess clinical, laboratory, imaging features, and outcomes of COVID-19 confirmed cases. Observational studies and also case reports, were included, and analyzed separately. We performed a random-effects model meta-analysis to calculate the pooled prevalence and 95% confidence interval (95%CI). RESULTS: 660 articles were retrieved for the time frame (1/1/2020-2/23/2020). After screening, 27 articles were selected for full-text assessment, 19 being finally included for qualitative and quantitative analyses. Additionally, 39 case report articles were included and analyzed separately. For 656 patients, fever (88.7%, 95%CI 84.5-92.9%), cough (57.6%, 40.8-74.4%) and dyspnea (45.6%, 10.9-80.4%) were the most prevalent manifestations. Among the patients, 20.3% (95%CI 10.0-30.6%) required intensive care unit (ICU), 32.8% presented with acute respiratory distress syndrome (ARDS) (95%CI 13.7-51.8), 6.2% (95%CI 3.1-9.3) with shock. Some 13.9% (95%CI 6.2-21.5%) of hospitalized patients had fatal outcomes (case fatality rate, CFR). CONCLUSION: COVID-19 brings a huge burden to healthcare facilities, especially in patients with comorbidities. ICU was required for approximately 20% of polymorbid, COVID-19 infected patients and hospitalization was associated with a CFR of over 13%. As this virus spreads globally, countries need to urgently prepare human resources, infrastructure and facilities to treat severe COVID-19."],"journal":"Travel Med Infect Dis","authors":["Rodriguez-Morales, Alfonso J","Cardona-Ospina, Jaime A","Gutierrez-Ocampo, Estefania","Villamizar-Pena, Rhuvi","Holguin-Rivera, Yeimer","Escalera-Antezana, Juan Pablo","Alvarado-Arnez, Lucia Elena","Bonilla-Aldana, D Katterine","Franco-Paredes, Carlos","Henao-Martinez, Andres F","Paniz-Mondolfi, Alberto","Lagos-Grisales, Guillermo J","Ramirez-Vallejo, Eduardo","Suarez, Jose A","Zambrano, Lysien I","Villamil-Gomez, Wilmer E","Balbin-Ramon, Graciela J","Rabaan, Ali A","Harapan, Harapan","Dhama, Kuldeep","Nishiura, Hiroshi","Kataoka, Hiromitsu","Ahmad, Tauseef","Sah, Ranjit"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32179124","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.tmaid.2020.101623","keywords":["Clinical features","Coronavirus disease 2019","Epidemic","Laboratory","Outcomes","SARS-CoV-2"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1661542092021694464,"score":223.9412},{"pmid":32178975,"title":"Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.","text":["Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.","BACKGROUND: Coronavirus disease 2019 (COVID-19) is a novel infectious disease with lack of established laboratory markers available to evaluate illness severity. In this study, we investigate whether platelet count could differentiate between COVID-19 patients with or without severe disease. Additionally, we evaluate if thrombocytopenia is associated with severe COVID-19. METHODS: An electronic search in Medline, Scopus and Web of Science was performed to identify studies reporting data on platelet count in COVID-19 patients. A meta-analysis was performed, with calculation of weighted mean difference (WMD) of platelet number in COVID-19 patients with or without severe disease and odds ratio (OR) of thrombocytopenia for severe form of COVID-19. RESULTS: Nine studies with 1779 COVID-19 patients, 399 (22.4%) with severe disease, were included in the meta-analysis. The pooled analysis revealed that platelet count was significantly lower in patients with more severe COVID-19 (WMD -31x10(9)/L; 95% CI, from -35 to -29x10(9)/L). A subgroup analysis comparing patients by survival, found an even lower platelet count was observed with mortality (WMD, -48x10(9)/L; 95% CI, -57 to -39x10(9)/L. In the four studies (n=1427) which reported data on rate of thrombocytopenia, a low platelet count was associated with over fivefold enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6). CONCLUSIONS: Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization.","Clin Chim Acta","Lippi, Giuseppe","Plebani, Mario","Michael Henry, Brandon","32178975"],"abstract":["BACKGROUND: Coronavirus disease 2019 (COVID-19) is a novel infectious disease with lack of established laboratory markers available to evaluate illness severity. In this study, we investigate whether platelet count could differentiate between COVID-19 patients with or without severe disease. Additionally, we evaluate if thrombocytopenia is associated with severe COVID-19. METHODS: An electronic search in Medline, Scopus and Web of Science was performed to identify studies reporting data on platelet count in COVID-19 patients. A meta-analysis was performed, with calculation of weighted mean difference (WMD) of platelet number in COVID-19 patients with or without severe disease and odds ratio (OR) of thrombocytopenia for severe form of COVID-19. RESULTS: Nine studies with 1779 COVID-19 patients, 399 (22.4%) with severe disease, were included in the meta-analysis. The pooled analysis revealed that platelet count was significantly lower in patients with more severe COVID-19 (WMD -31x10(9)/L; 95% CI, from -35 to -29x10(9)/L). A subgroup analysis comparing patients by survival, found an even lower platelet count was observed with mortality (WMD, -48x10(9)/L; 95% CI, -57 to -39x10(9)/L. In the four studies (n=1427) which reported data on rate of thrombocytopenia, a low platelet count was associated with over fivefold enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6). CONCLUSIONS: Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization."],"journal":"Clin Chim Acta","authors":["Lippi, Giuseppe","Plebani, Mario","Michael Henry, Brandon"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32178975","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.cca.2020.03.022","keywords":["coronavirus, COVID-19","platelets","thrombocytopenia"],"source":"PubMed","locations":["Scopus","Medline","thrombocytopenia","Thrombocytopenia"],"topics":["Mechanism"],"weight":1,"_version_":1661542092015403009,"score":189.37437},{"pmid":32173574,"title":"Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis.","text":["Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis.","BACKGROUND: An outbreak of Novel Coronavirus (COVID -19) in Wuhan, China, the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of the meta-analysis was to assess the prevalence of comorbidities in the COVID-19 infection patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of sciences until February 25, 2020. Risk ratio (OR) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Eight studies were included in the meta- analysis, including 46248 infected patients. The result showed the most prevalent clinical symptom was fever ( 91 +/- 3, 95% CI 86-97% ), followed by cough (67 +/- 7, 95% CI 59-76%), fatigue ( 51 +/- 0, 95% CI 34-68% ) and dyspnea ( 30 +/- 4, 95% CI 21-40%). The most prevalent comorbidity were hypertension (17 +/- 7, 95% CI 14-22%) and diabetes ( 8 +/- 6, 95% CI 6-11% ), followed by cardiovascular diseases ( 5 +/- 4, 95% CI 4-7% ) and respiratory system disease( 2 +/- 0, 95% CI 1-3% ). Compared with the Non-severe patient, the pooled odds ratio of hypertension, respiratory system disease, cardiovascular disease in severe patients were (OR 2.36, 95% CI: 1.46-3.83), (OR 2.46, 95% CI: 1.76-3.44) and (OR 3.42, 95% CI: 1.88-6.22)respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 infection patients and found underlying disease, including hypertension, respiratory system disease and cardiovascular, may be a risk factor for severe patients compared with Non-severe patients.","Int J Infect Dis","Yang, Jing","Zheng, Ya","Gou, Xi","Pu, Ke","Chen, Zhaofeng","Guo, Qinghong","Ji, Rui","Wang, Haojia","Wang, Yuping","Zhou, Yongning","32173574"],"abstract":["BACKGROUND: An outbreak of Novel Coronavirus (COVID -19) in Wuhan, China, the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of the meta-analysis was to assess the prevalence of comorbidities in the COVID-19 infection patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of sciences until February 25, 2020. Risk ratio (OR) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Eight studies were included in the meta- analysis, including 46248 infected patients. The result showed the most prevalent clinical symptom was fever ( 91 +/- 3, 95% CI 86-97% ), followed by cough (67 +/- 7, 95% CI 59-76%), fatigue ( 51 +/- 0, 95% CI 34-68% ) and dyspnea ( 30 +/- 4, 95% CI 21-40%). The most prevalent comorbidity were hypertension (17 +/- 7, 95% CI 14-22%) and diabetes ( 8 +/- 6, 95% CI 6-11% ), followed by cardiovascular diseases ( 5 +/- 4, 95% CI 4-7% ) and respiratory system disease( 2 +/- 0, 95% CI 1-3% ). Compared with the Non-severe patient, the pooled odds ratio of hypertension, respiratory system disease, cardiovascular disease in severe patients were (OR 2.36, 95% CI: 1.46-3.83), (OR 2.46, 95% CI: 1.76-3.44) and (OR 3.42, 95% CI: 1.88-6.22)respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 infection patients and found underlying disease, including hypertension, respiratory system disease and cardiovascular, may be a risk factor for severe patients compared with Non-severe patients."],"journal":"Int J Infect Dis","authors":["Yang, Jing","Zheng, Ya","Gou, Xi","Pu, Ke","Chen, Zhaofeng","Guo, Qinghong","Ji, Rui","Wang, Haojia","Wang, Yuping","Zhou, Yongning"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32173574","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.ijid.2020.03.017","keywords":["2019-nCoV","COVID-19","Clinical characteristics","Comorbidities","Epidemiologicalm","Meta-analysis"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1661456248860573697,"score":188.62012}]}